C9orf142 Activators

The chemical class termed as C9orf142/BRASA1 activators encompasses a range of compounds that indirectly modulate the activity of C9orf142/BRASA1 through their influence on the ubiquitin-proteasome system and related deubiquitination processes. These compounds are diverse, including both targeted small molecule inhibitors and natural compounds with broad biological activities. Proteasome inhibitors like MG132 and Bortezomib represent a key group in this class. By inhibiting the proteasome, these compounds lead to an accumulation of ubiquitinated proteins, potentially impacting the function of C9orf142/BRASA1 in the deubiquitination process. Thalidomide and its derivatives, known for their immunomodulatory effects, also affect the ubiquitin-proteasome system, thereby potentially influencing C9orf142/BRASA1 activity.

MLN4924, targeting the NEDD8-activating enzyme, affects ubiquitin-like protein pathways, which are closely related to the ubiquitination and deubiquitination processes where C9orf142/BRASA1 might play a role. Inhibitors like IU1, PR-619, LDN-57444, and WP1130, which target various deubiquitinating enzymes, also indirectly influence the functional environment of C9orf142/BRASA1. Natural compounds such as Curcumin and Resveratrol are included due to their ability to modulate multiple cellular pathways, including those related to protein ubiquitination and stability. These compounds, through their wide-ranging effects on cellular signaling and proteostasis, might impact C9orf142/BRASA1 activity. Lastly, compounds like Disulfiram and Chloroquine, though not directly linked to deubiquitinating processes, interact with components of the ubiquitin-proteasome system and lysosomal degradation pathways, respectively. These interactions could potentially influence the activity of C9orf142/BRASA1. This chemical class highlights the complexity of targeting specific protein functions through indirect modulation. By influencing the broader ubiquitin-proteasome system and related pathways, these compounds offer potential avenues to modulate C9orf142/BRASA1 activity, reflecting the interconnected nature of cellular proteostasis networks.